David Setboun, Pharm.D., MBA

David Setboun, Pharm.D., MBA, is a life sciences CEO with more than 20 years of experience building and scaling biotech and pharmaceutical organizations across neurology, rare disease, oncology, and aging science. He has held senior leadership roles at Eli Lilly, AstraZeneca, and Biogen, where he led initiatives in corporate development, commercial strategy, and global operations, including multiple product launches, portfolio transformations, and strategic partnerships with large pharmaceutical companies and academic centers. As Chief Executive Officer of Pharmatrophix, David leads a clinical‑stage neurodegeneration company advancing first‑in‑class p75 neurotrophin receptor modulators with the potential to change the trajectory of Alzheimer’s disease and rare neurodegenerative disorders, including progressive supranuclear palsy and Huntington’s disease. He oversees the company’s clinical and corporate strategy, including the expansion of its mid‑stage clinical pipeline, global collaborations, and financing activities aimed at bringing disease‑modifying treatments to patients with high unmet medical need.